| |
| |
| Catalent Invests $130 Million to Add Manufacturing Capacity at its Gene Therapy Campus in Harmans, Maryland |
|
|
|
|
|
| Catalent will add five Phase 3 through commercial-scale suites to its gene therapy campus in Harmans, to support a growing customer pipeline and market demand. The campus comprises two state-of-the-art facilities that, when completed, will house a total of 15 gene therapy suites each designed to accommodate multiple bioreactors for commercial supply. |
|
|
| | |
|
|
| |
| |
| Catalent to be Added to S&P 500 Index
“This designation is an affirmation of our strategy and the substantial progress we have made in executing it since our IPO in 2014,” commented John Chiminski, Chair and CEO, Catalent. “None of this would have been possible without the passion and dedication of our 14,000 employees, whose commitment to our mission to help people live better, healthier lives has propelled Catalent to where we are today.” |
|
|
|
|
|
| |
| |
| Catalent is Proud to Support Many High-Profile Covid-19 Programs
Catalent is working with over 50 customers on multiple COVID-19-related antivirals, vaccines, diagnostics and treatments for symptoms and effects of virus. Find out more. |
|
|
|
|
|
| |
| |
| T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy
Catalent will provide technology transfer and CGMP clinical manufacturing of T-knife’s T1367 T-cell receptor program. T1367 is an autologous T-cell receptor-based cell therapy derived from T-knife’s proprietary humanized T-cell receptor (HuTCR) mouse platform and specifically targets MAGE-A1 positive tumors in cancer patients. |
|
|
|
|
|
| |
| |
| |
| |
| |
| Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line at its Bloomington, Indiana Facility
Expected to be operational by April 2021, the new line will add capacity to support the growing pipeline of clinical programs and commercial launches at the site. Learn more |
|
|
|
|
|
| |
| Join Our Experts at Live Virtual Events to Hear the Latest on Covid-19 and Technology Development Programs |
|
|
|
|
|
| Catalent Events
Endpoints 11 Awards: Start-ups to Watch | September 30 | Virtual Event
John Carroll, Founder and Editor of Endpoints News, and John Chiminski, CEO & Chair of Catalent, will be co-hosting the “Endpoints 11 – Startups to Watch Awards”, a one-hour virtual event that celebrates innovative science and entrepreneurship.
CPhI Festival of Pharma | October 5 - 16 | Virtual Conference
During this two-week event, Julien Meissonnier, Chief Scientific Officer, will participate in a roundtable titled “Innovation in Oncology Development”, while Thomas VanCott, Ph.D., Global Head of Product Development, Cell & Gene Therapy, will participate in the “Cell & Gene Technology” roundtable. Cornell Stamoran, Ph.D., Vice President of Corporate Strategy, Catalent, will also participate, in The Medicine Maker roundtable, “Facing the COVID-19 Crisis: Leadership and the Future of Pharma”.
AAPS PharmaSci 360 | October 26 - November 5 | Virtual Conference
Lisa Caralli, Director, Science & Technology, Pharmaceutics, will present “Data-Driven Strategies to Accelerate Your Molecule’s Development Path”. Dr. Stamoran and William Chin, Ph.D., Manager, Global Scientific Affairs, will present “Patient-Focused Drug Design: A Structured Approach to Dose Form Design to Develop Better Treatments that Address Patient Needs”.
Biologics Events
BioProcess International | September 21 - 25 | Virtual Conference
Humanigen and Catalent Biologics will present a case study on the rapid scale up of Humanigen’s investigational COVID-19 therapeutic candidate, lenzilumab, and will discuss how the two companies have collaborated to get lenzilumab to patients as quickly as possible.
PDA Universe of Pre-Filled Syringes & Injection Devices | October 5 - 8 | Virtual Event
Pam Barton, Senior Manager, Manufacturing Technology, Catalent Biologics, will present “The Faster Path to Self-Administration: Moving from Pre-Filled Syringe to Auto-Injector”.
Webinar | Advancing Your Biologics Drug Product | October 22
Register to attend “Advancing Your Biologics Drug Product: Strategies for Successful Formulation, Tech Transfer and Delivery System”, to hear insights from Kevin Lance, Ph.D., Marketing Manager, Unchained Labs, Natasha Van Rutten, Director, Product Development, Catalent Biologics, and Ian Thompson, Vice President, Business Development, Ypsomed. |
|
|
|
|
|
|
Cell & Gene Therapy
World Vaccine Congress | September 28 - October 1 | Virtual Conference
On Sept.30, George Buchman, Ph.D., Vice President of Preclinical & Process Development, Catalent Cell & Gene Therapy, will present “Next-Generation Vaccines and Oncolytic Viruses: Current Challenges and Future Promise”.
Cell Therapy Manufacturing & Gene Therapy Congress | October 19 - 22 | Virtual Conference
Jesse Trekker, Ph.D., Business Manager, Catalent Cell & Gene Therapy, will present “How to Commercially Scale T-Cell Allogeneic Therapies”.
Allogeneic Cell Therapies Summit 2020 | October 26 - 28 | Virtual Conference
James Crutchley, Ph.D., Process Engineer at Catalent Cell & Gene Therapy will speak to the challenges associated with scaling up T-cell allogeneic therapies.
Clinical Supply Services
GCSG 2020 Global Virtual Conference | September 21 - 25 | Virtual Conference
Distribution planning post-Covid-19, direct-to-patient supply, and protocol interpretation to be discussed by Catalent Clinical Supply experts at GCSG Virtual.
Oral Drug Delivery
Drug Delivery Partnership | September 21 - 24 | Virtual Conference
Dr. Stamoran will moderate the “Patient Inclusion During Design: From Human Factors Studies to Patient Boards” panel session, as part of the “Drug Delivery Partnerships 2” stream.
Webinar | From Candidate to Clinic: Strategies to Accelerate Your Molecule’s Development Path | September 23
Industry experts will introduce a fast and efficient development process that can help deliver the right clinical candidate, best formulation strategy, and an optimal dosage form to Phase 1.
Contract Pharma Conference | September 23 - October 8 | Web Series
Mark Saunders, Consultant, P2C-Pharma Ltd., and Catalent Scientific Advisory Board Member will present “Key Success in Accelerating Early to Mid-Phase Drug Development Program for Poorly Soluble Drugs” on Oct. 1.
Manufacturing Chemist Live | October 28 - 29 | Birmingham, U.K.
Christopher Harrison, Director of Manufacturing Operations, Catalent, will discuss some of the key issues to consider when planning for the scale-up of a small molecule development program, with a focus on highly potent drugs.
Webinar | Immune-Health Supplement Drivers: Trends & Innovation in Ingredients & Delivery | September 22 During this webcast, experts in immune health will discuss the role that certain nutrients play in immune health, and highlight which ones are likely to trend strongly with consumers. |
|
|
|
|
|
| A Catalyst in Drug Development | | Stephie Lee, M.S. Scientist, San Diego, California |
|
|
|
|
|
| Stephie Lee, M.S., is a Scientist at Catalent at our San Diego California facility. She has a broad background in preclinical and clinical formulation, Stephie has managed more than 60 oral formulation programs, including spray dried dispersion, fluid bed processing, and micronization projects. Learn what drives her commitment to researching solubility and GLP formulations. Access her works on bioavailability enhancements, early phase development techniques, and best practices for formulation screening. |
|
|
| | |
|
|
| |
| |
| |
| |
| |
| |
| |
| |
| At Catalent, you will have the opportunity to thrive in a fast-paced, innovative environment where maximizing your potential isn’t just your own personal goal, it’s ours too. Our teams are rapidly growing in Harmans, MD, Madison, WI, Schorndorf, Germany and multiple other locations. Apply today!
Interested in working in Gene Therapy? Click here to view our openings. |
|
|
| | |
|
|
| |
| Every brand has a challenge. We have a solution. | | | | or call +1 877 891 9609 to speak with one of our experts today! | | |
|
|
|
|
|
| |
| To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at [email protected], or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2020, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
|
|
| |
